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ArticleDual arginine recognition of LRRK2 phosphorylated
Rab GTPasesDieter Waschb€usch,1 Elena Purlyte,2 and Amir R. Khan3,*
1School of Biochemistry and Immunology, Trinity College Dublin, Dublin, Ireland; 2MRC Protein Phosphorylation and Ubiquitylation Unit,
School of Life Sciences, University of Dundee, Dundee, United Kingdom; and 3Division of Newborn Medicine, Boston Children’s Hospital,
Boston, MassachusettsABSTRACT Parkinson’s-disease-associated LRRK2 is a multidomain Ser/Thr kinase that phosphorylates a subset of Rab
GTPases to control their effector functions. Rab GTPases are the prime regulators of membrane trafficking in eukaryotic cells.
Rabs exert their biological effects by recruitment of effector proteins to subcellular compartments via their Rab-binding domain
(RBD). Effectors are modular and typically contain additional domains that regulate various aspects of vesicle formation,
trafficking, fusion, and organelle dynamics. The RBD of effectors is typically an a-helical coiled coil that recognizes the GTP
conformation of the switch 1 and switch 2 motifs of Rabs. LRRK2 phosphorylates Rab8a at T72 (pT72) of its switch 2 a-helix.
This post-translational modification enables recruitment of RILPL2, an effector that regulates ciliogenesis in model cell lines. A
newly identified RBD motif of RILPL2, termed the X-cap, has been shown to recognize the phosphate via direct interactions
between an arginine residue (R132) and pT72 of Rab8a. Here, we show that a second distal arginine (R130) is also essential
for phospho-Rab binding by RILPL2. Through structural, biophysical, and cellular studies, we find that R130 stabilizes the
primary R132:pT72 salt bridge through favorable enthalpic contributions to the binding affinity. These findings may have impli-
cations for the mechanism by which LRRK2 activation leads to assembly of phospho-Rab complexes and subsequent control of
their membrane trafficking functions in cells.SIGNIFICANCE Parkinson’s-disease-associated LRRK2 kinase phosphorylates Rab8a and Rab10 to subvert their
membrane trafficking functions in the formation of primary cilia. Rab8a is phosphorylated at a threonine (pT72) and
subsequently binds to a phosphospecific effector (RILPL2) via its C-terminal RH2 domain. Here, we show that recognition
of pT72 involves a dual arginine motif involving R130 and R132 from the RH2 domain of RILPL2. Thermodynamic and
structural studies suggest that the phosphospecific interactions are highly sensitive to the upstream region, which includes
the N-terminal RH1 domain that binds to myosin Va. The dual arginine motif may facilitate the dynamic nature of membrane
trafficking processes involving phosphorylation of Rabs.INTRODUCTION
Rab GTPases belong to the Ras superfamily of GTP/GDP-
binding molecular switches that regulate membrane traf-
ficking in eukaryotic cells (1). GTP/GDP exchange factors
(GEFs) convert Rabs into their GTP form and are involved
in directing them onto distinct subcellular compartments via
their prenylated C-terminal cysteine residues. The switch 1
and 2 regions of Rabs undergo local conformational changes
during the nucleotide exchange that enable recruitment of
GTP-specific cytosolic effector proteins (2). Rabs are turnedSubmitted January 27, 2021, and accepted for publication March 3, 2021.
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creativecommons.org/licenses/by/4.0/).off through the action of GTPase activating proteins (GAPs)
that aid the hydrolysis of the g-phosphate of GTP. In recent
years, several Rab GTPases have been shown to be targets of
protein kinases (3). Phosphorylation of Rabs has emerged as
a mechanism for tuning Rab functions through control of the
strength of their interactions with GEFs, GAPs, and effector
proteins. Many Rabs link directly or indirectly to motor pro-
teins (myosin, dynein, and kinesin) and their associated
adaptors (4). Rab connections to the cytoskeleton control
processes such as vesicle trafficking, organelle structure,
and dynamics (2,5). However, the molecular basis for phos-
phodependent control of membrane trafficking by Rab
GTPases is poorly understood.
We have recently described a novel X-cap motif that en-
ables the RILP family of effectors to bind to phosphorylated
Dual arginine binding of phospho-RabsRab GTPases (6). The N-terminal RH1 (RILP homology)
domain of the cytosolic adaptor Rab-interacting lysosomal
protein-like 2 (RILPL2) binds to the globular tail domain
of myosin Va (7). The C-terminal RH2 domain of RILPL2
encodes a Rab-binding domain (RBD) that adopts a parallel
a-helical coiled-coil structure. The N-terminus of the RBD
forms an X-cap motif that resembles a hook that winds
around its partner. This motif is stabilized by a short antipar-
allel b-strand-like interaction and has an overall X-shaped
conformation that caps the a-helical coiled coil. In the struc-
ture of pRab8a with a minimal RBD (residues 129–165), the
X-cap enables projection of an Arg residue (R132RL2) from
each monomer toward a phosphorylated threonine residue
of Rab8a (pT72R8). In cells, the kinase LRRK2 phosphory-
lates Rab8a and Rab10 at conserved threonine residues in
the switch 2 region, and the post-translational modification
tunes the strength of Rab interactions with their binding
partners (8). Rab8a/10 phosphorylated at pT72/pT73 recruit
RILPL2 to membranes and affect the growth of primary
cilia in model cell lines (9). In previous work, we also
showed that myosin Va binding to RILPL2 enhances its af-
finity for pRab8a through an unknown mechanism (6).
LRRK2 is the leading cause of inherited Parkinson’s dis-
ease, a disorder of the central nervous system that manifests
as a progressive degeneration of motor mobility, balance,
and tremors. Phosphodependent recruitment of RILPL2 by
pRab8a/10 is a part of the underlying molecular pathways
that connect LRRK2 to neuronal degeneration (10). There-
fore, it is critical to understand the biophysical processes
that underpin Rab regulatory pathways associated with Par-
kinson’s disease.
Here, we have determined the structure of pRab8a in a
complex with an extended RBD of RILPL2 (117–165;
abbreviated as RL2117) at 1.9-Å resolution. The structure in-
cludes residues preceding the X-cap that were not mapped
in our previous work. In addition, we have determined the
structure of the phosphomimetic T72E mutant of Rab8a
(Rab8TE) in complex with the minimal RBD of RILPL2
(129–165; RL2129) at 1.7-Å resolution. These two structures
are analyzed in comparison to the previously published
structure of pRab8a in complex with the minimal RBD of
RILPL2 (129–165; RL2129). We find that the overall struc-
tures are identical in all three complexes with no significant
differences in intermolecular contacts. However, there are
dramatic conformational changes localized to two arginine
residues (R130RL2, R132RL2) in the X-cap of RILPL2.
The complex with the extended RBD (RL2117) has two
well-ordered stacked arginines in which R130 appears to
stabilize the conformation of R132, which directly forms a
salt bridge to the pT72R8. The other two complexes display
various levels of disorder, suggesting an influence of the up-
stream residues of RILPL2 on pRab8a recognition. Calo-
rimetry reveals that RL2117 has a significantly higher
affinity for pRab8a relative to RL2129. We conclude that a
robust interaction between the RILP family of effectorsBPJ 110with cognate phospho-Rabs is dependent on a dual arginine
recognition motif. Mutation of distal R130 to lysine/gluta-
mine is sufficient to abolish interactions with pRab8a in
cells. The apparent sensitivity of the dual arginine motif to
the upstream region of RILPL2 suggests a mechanism by
which myosin:RILPL2 complex formation may regulate
its recruitment to phospho-Rab8a membranes.MATERIALS AND METHODS
Escherichia coli expression constructs
The E. coli expression optimized cDNA for Rab8a was obtained from Gen-
script and covers the residues 1–181 of human Rab8a (Q67L; Q67L þ
T72E), as previously described (6). The Q67L mutation maintains the
Rab8a in the active GTP-bound conformation. The cDNA was cloned
into the pET28a vector using NdeI/BamHI cloning sites and provides a hex-
ahistidine tag that is cleavable by thrombin. The cDNA for human
RILPL2117165 was amplified by PCR from a human full-length RILPL2
construct in pET28a (6) using the following primers: 50-C CAG GGA
GCA GCC TCG GGC CCG AAC AAG ATG GTG G-30 (forward); 50-
GC AAA GCA CCG GCC TCG TTA ACC GCT TTT GTA GCA TTG
CAG-30 (reverse). Similarly, the cDNA for human RILPL2129165 was
made using the following primers: 50-C CAG GGA GCA GCC TCG
AAC CGT CCG CGT TTC ACC C-30 (forward); 50-GC AAA GCA CCG
GCC TCG TTA ACC GCT TTT GTAGCATTG CAG-30 (reverse). The re-
sulting DNAwas cloned using ligation-independent methods into the pLIC-
MBP vector (11). The construct was sequenced and transformed into E. coli
BL21(DE3) for expression as His6-MBP-(TEV)-RILPL2
117165.Protein production
Expression of Rab8a was carried out in LB (Miller) broth supplemented
with antibiotic (34 mg/mL kanamycin or 100 mg/mL ampicillin) at 37C.
Media, chemicals, and antibiotics were obtained from FORMEDIUM. At
an OD600 of 0.6, the culture was cooled to 18
C for 1 h and induced
with 0.5 mM IPTG, after which cells were grown overnight at 18C.
Expression of His6-MBP-RILPL2117-165 was carried out in LB (Miller) me-
dium supplemented with 100 mg/mL ampicillin (FORMEDIUM) at 37C.
At an OD600 of 0.6–0.8, the culture was induced with 0.5 mM IPTG. Cells
were grown for an additional 4 h at 37C. After induction, cells were har-
vested by centrifugation, and the pellets were resuspended in His-tag
extraction buffer (20 mM Tris-HCl, 300 mM NaCl, 10 mM imidazole,
and 10 mM b-mercaptoethanol (pH 8.0); þ5 mM MgCl2 for Rab con-
structs). Cells were lysed by sonication, and the cell lysate was centrifuged
at 26,000 g for 45 min at 4C to remove cellular debris. The supernatants
were loaded onto an Ni2þ-agarose resin (Qiagen). The resin was washed
with a 10-fold excess of extraction buffer followed by washing with a five-
fold excess using the same buffer supplemented with 40 mM imidazole
before elution of the bound proteins using extraction buffer supplemented
with 200 mM imidazole. The eluted proteins were dialyzed against
20 mM Tris-HCl, 100 mM NaCl, 5 mM MgCl2, and 1 mM DTT (pH
7.5). Overnight incubation at 4C with thrombin (GE Healthcare) or TEV
protease was used to remove the N-terminal hexahistidine or hexahisti-
dine-MBP tags from each protein. After cleavage, the proteins were run
through a second Ni2þ-agarose column. The flow-through fractions were
collected, while the uncut proteins remained bound to the resin. The peptide
corresponding to residues 129–165 of RILPL2 was synthesized with an
N-terminal hexahistidine tag (GenScript). The peptide was solubilized in
aqueous buffer (20 mM Tris-HCl, 100 mM NaCl, 5 mM MgCl2, 1 mM
DTT (pH 7.5)) before crystallization trials.
The second nickel procedure was repeated to minimize the amount of
uncleaved His6-MBP-RILPL2 precursor. Cut RL2
117 was dialyzed into74
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Waschb€usch et al.low-salt buffer (10 mMMES, 10 mMNaCl, 1 mMDTT (pH 6.0)). The pro-
tein was then loaded onto a MonoS cation exchange column (GE Health-
care). The column was subjected to a gradient from low-salt buffer into a
high-salt buffer (10 mM MES, 1 M NaCl, 1 mM DTT (pH 6.0)) over a
30-mL volume. The collected fractions were analyzed by SDS-PAGE to
ensure purity of RL2117.
After removal of the hexahistidine tag, Rab8a was further purified by
running the protein through a Superdex 75 (16/60) gel filtration column
(GE Healthcare) equilibrated in column buffer (20 mM Tris-HCl, 100 mM
NaCl, 5 mM MgCl2, 1 mM DTT (pH 7.5)). The peak fraction containing
pure protein was collected and concentrated before crystallization and bio-
physical experiments. The phosphorylation of Rab8a by MST3 kinase and
its specificity to T72 have been described in detail (6). In brief, Rab8a was
mixed with MST3 at an 8:1 molar ratio, and the buffer was adjusted to the
following conditions: 50 mM Tris-HCl, 150 mM NaCl, 10 mM MgCl2,
2 mM ATP (pH 7.5). Phosphorylation took place at room temperature over-
night. The phosphorylation mixture was dialyzed against low-salt buffer and
loaded to a MonoS (GE Healthcare) column. Phosphorylated Rab8a was
separated from unphosphorylated Rab8a by ion exchange chromatography
by a 50% gradient from a 10 mM to 1 M salt buffer (10 mM MES, 5 mM
MgCl2, 1 mM DTT (pH 5.2)). The phosphorylation of Rab8a was confirmed
by PhosTag gel electrophoresis before subsequent experiments.Crystallization, data collection, and refinement
Crystals of Rab8TE:RL2129 complex were obtained in a 1:2 molar ratio of
protein/peptide at a total of 12 mg/mL. Crystals were grown in 100 mM
HEPES buffer (pH 7), 10% PEG 4000, and 10% 2-propanol. Plate-like crys-
tals were harvested in precipitant supplemented with 25% glycerol and
stored frozen in liquid nitrogen. X-ray data were collected under a cryo-
genic nitrogen stream at 100 K (beamline 24-ID-C; Advanced Photon
Source). Crystals of pRab8(Q67L):RL2117 complex were obtained in a
1:1 molar ratio of protein/peptide at a total concentration of 5 mg/mL. Crys-




Space group P 21
Asymmetric unit 2 Rab8a
Cell (a, b, c, Å) 36.09, 118.38, 39.6
(a,b,g,) 90, 101.96, 90
Resolution (Å) 29.29–1.72 (1.76–1.72)
Number of reflections: total (unique) 144,140 (32,822)








R-free test size 1632 (163)
RMSD bond lengths (Å) 0.006
RMSD bond angles () 0.86
Average overall B-factor 19.83
Mean B-factors (Å2) protein/GTP/waters 18.92/14.64/29.12
Ramachandran analysis favored/allowed (%) 97.96/2.04
PDB accession code 6whe
Values in parentheses correspond to the statistics in the highest resolution bi
ShklFo,hkl.
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1848 Biophysical Journal 120, 1846–1855, May 4, 2021PEG3350. Rod-like crystals were harvested in precipitant supplemented
with 25% glycerol and stored frozen in liquid nitrogen. X-ray data were
collected under a cryogenic nitrogen stream at 100 K (beamline 24-ID-C;
Advanced Photon Source).
Native diffraction data were reduced using XDS and Aimless, followed
by structure determination using the Phaser software in the PHENIX
package (12,13). Structures were solved using Rab8a (Protein Data Bank,
PDB: 4lhw) (14) and RILPL2 (PDB: 6rir) as search models. Because the
Rab8TE:RL2129 crystals are isomorphous to the previously determined pRa-
b8a:RL2129 structure (6), identical reflections were flagged for the R-free
subset. Refinement was performed using multiple rounds of model building
and energy minimization using PHENIX and COOT (15). The asymmetric
unit contains two molecules of Rab8TE (chain A: 2–177; B: 4–176) bound
to GTP and two molecules of the RILPL2 (chain D: 129–159; E: 129–160).
The structure of pRab8a:RILPL2117165 was solved and refined in a similar
manner. However, the space group is different, and the asymmetric unit
consists of one molecule of pRab8 and one molecule of RL2117. Details
of data collection, structure refinement, and deposited PDB files are shown
in Table 1. Unless indicated, structures were typically aligned using the sec-
ondary structure matching algorithm implemented in COOT. The Ca atoms
of (p)Rab8a in the various structures typically aligned with a root mean-
square displacement (RMSD) of 0.4–0.6 Å.Pulldowns and isothermal titration calorimetry
For in vitro pulldowns, hexahistidine-tagged full-length RILPL2 (1–211) or
hexahistidine-MBP-tagged truncated RILPL2 constructs were used. Rabs
and RILPL2 constructs (10 mM each) were mixed together in 1.5-mL
centrifuge tubes with 25 mL Ni2þ- agarose resin in a final volume of
1 mL of binding buffer (20 mM Tris (pH 8.0), 300 mM NaCl, 20 mM imid-
azole, 5 mMMgCl2, 10 mM b-mercaptoethanol). The reaction mixture was
mildly shaken for 15 min followed by gentle centrifugation (1000 rpm). The
resin was washed three times with 1 mL of the binding buffer. After release
of proteins from resin with 50 mL elution buffer (20 mM Tris-Cl (pH 8.0),Rab8TE:RILPL2 (129–165) pRab8a:RILPL2 (117–165)
NECAT APS, 24-ID-C NECAT APS, 24-ID-E
0.9789 0.97918
P 21 21 21 C 2 2 21
2 Rab8a, 2 RILPL2 1 Rab8a, 1 RILPL2
60.698, 71.733, 116.39 62.773, 68.43, 128.1
90, 90, 90 90, 90, 90
61.07–1.684 (1.744–1.684) 46.26–1.9 (1.968–1.9)
325,450 (10,484) 183,379 (15,819)
96.86 (79.50) 96.02 (90.3)
20.31 (2.44) 16.79 (0.35)
5.7 (2.3) 8.6 (7.9)
0.0543 (0.403) 0.05713 (4.301)
0.998 (0.584) 0.999 (0.54)
0.1815 (0.3305) 0.2187 (0.5266)
0.2028 (0.3577) 0.2669 (0.5685)







n. Rmerge ¼ Shkl SjrIhkl,j–<Ihkl>r/Shkl Sjhkl,j. Rwork ¼ ShklrFo,hkl–Fc,hklr/
Dual arginine binding of phospho-Rabs300 mM NaCl, 200 mM imidazole), samples were subjected to SDS-PAGE
and visualization with 0.5% Coomassie Brilliant Blue.
Calorimetry experiments were performed in triplicate. The N-terminal
polyhistidine-tagged RILPL2 peptide (His6-RILPL2
129165), or recombi-
nantly expressed RILPL2117165, was dialyzed together with pRab8a/
Rab8TE (20 mM Tris-HCl, 150 mM NaCl, 5 mM MgCl2, and 1 mM
DTT (pH 7.5)). Protein concentrations were calculated based on their
A280 using an ND-1000 NanoDrop spectrophotometer (Thermo Scientific).
Samples were centrifuged at 13,200 rpm for 10 min before the determina-
tion of protein concentration and ITC analyses. Injection of Rab8TE/pRab8a
into RILPL2 was performed, rather than the other way around. RILPL2 in-
jections into buffer revealed a large heat of dilution, which complicated es-
timates of binding enthalpy and Kd. The concentrations of proteins for
injections were between 400 and 600 mM Rab8a and 40–60 mM RILPL2.
Data were processed using Origin 7.0 with the ITC plug-in.Plasmids for cellular assays
The plasmids used for coimmunoprecipitation experiments were acquired
from MRC PPU Reagents and Services (https://mrcppureagents.dundee.ac.
uk/reagents-proteins/overview): GFP-empty pcDNA5 FRT/TO (DU13156);
Flag-LRRK2 Y1699C pCMV (DU13165); HA-Rab8a WT pCMV
(DU35414); RILPL2-GFP WT pcDNA5D FRT/TO (DU27481); RILPL2-
GFP P128A pcDNA5D FRT/TO (DU68411); RILPL2-GFP D127A
pcDNA5D FRT/TO (DU68427); RILPL2-GFP D127N pcDNA5D FRT/TO
(DU68428); RILPL2-GFP T126A pcDNA5D FRT/TO (DU68412);
RILPL2-GFP D124N pcDNA5D FRT/TO (DU68429); RILPL2-GFP
D124A pcDNA5D FRT/TO (DU68413).Antibody reagents
Antibodies used in this study were diluted in 5% w/v bovine serum albumin
in TBS supplemented with 0.1% Tween-20 (TBS-T) and 0.03% w/v sodium
azide. The rabbit monoclonal antibody for total LRRK2 (N-terminus) was
purified at the University of Dundee (16). Anti-GFP (PABG1; Chromotek,
used at 1:1000), anti-HA (3F10; Merck, used at 1:1000), anti-pT72-Rab8a
(MJF-R20; Abcam, used at 0.5 mg/mL), anti-LRRK2 C-terminal (N241A/
34; Neuromab, used at 1:1000), and anti-a-tubulin (3873S; CST, used at
1:5000). Secondary antibodies used were LI-COR IRDye for 800CW
goat anti-rabbit (925–32211), goat anti-mouse (926–32210), and 680LT
goat anti-rat (925–68029) and goat anti-mouse (926–68020), all used at
1:10,000 dilution in TBS-T.Culture and transfection of cells
HEK293 cells were cultured in Dulbecco’s modified Eagle medium (Gluta-
max; Gibco) supplemented with 10% fetal bovine serum (Sigma), 100 U/
mL penicillin, and 100 mg/mL streptomycin. Transient transfections were
performed 40–48 h before cell lysis using polyethylenimine PEI (Poly-
sciences) at around 60–70% confluence. Transfections for coimmunopreci-
pitation experiments were done in 10-cm round cell culture dishes using 3
mg of Flag-LRRK2 Y1699C, 1 mg of HA-Rab8a, and 1 mg of GFP control or
RILPL2-GFP cDNA construct per dish diluted in 1 mL of OPTIMEM me-
dia and supplemented with 20 mg of PEI, incubated for 20 min before being
added to the cell media. At 90 min before lysis, cells were treated with
500 nM of MLI-2 inhibitor or 0.1% DMSO control.Coimmunoprecipitation of Rab8a and RILPL2
Cells were washed with phosphate-buffered saline and lysed in lysis
buffer—50 mM Tris-HCl (pH 7.5), 1 mM EGTA, 10 mM sodium b-glycer-
ophosphate, 50 mM sodium fluoride, 5 mM sodium pyrophosphate 
10H2O, 0.27 M sucrose—and supplemented fresh before lysis with 1% v/BPJ 110v Triton-x100, one tablet of cOmplete Mini (EDTA-free) protease inhibitor
(11836170001; Merck) per 10 mL of buffer, 0.1 mg/mL of microcystin, and
1 mM of sodium orthovanadate. Lysates were clarified by centrifugation at
17,000  g for 10 min. For GFP immunoprecipitation, lysates were incu-
bated with nanobody a-GFP binder Sepharose from MRC PPU Reagents
and Services for 1 h at 4C (15 mL of packed resin/0.5 mg of lysate). Bound
complexes were recovered by washing the beads three times with wash
buffer (50 mM Tris-HCl (pH 7.5), 150 mM NaCl) before eluting with 2
SDS-PAGE sample buffer supplemented with 1% v/v 2-mercaptoethanol.
The samples were denatured at 70C for 10 min, and the resin was separated
from the sample by centrifugation through a 0.22-mm Spinex column
(CLS8161; Sigma). Samples were subjected to immunoblotting.Gel electrophoresis and immunoblot analysis
Samples were run on gels consisting of a 4%w/v acrylamide stacking gel (4%
w/v acrylamide, 0.125 M Tris-HCl (pH 6.8), 0.2% v/v tetramethylethylenedi-
amine, and 0.08% w/v ammonium persulfate (APS)) and 10% w/v acryl-
amide separating gel (10% w/v acrylamide, 0.375 M Bis-Tris (pH 6.8), 1%
v/v tetramethylethylenediamine, and 0.05% w/v APS) in MOPS buffer
(50 mMMOPS, 50 mMTris, 1 mMEDTA, 0.1%w/v SDS) at 90–120 V. Pro-
teins were electrophoretically transferred onto nitrocellulose membranes
(Amersham Protran 0.45 mm nitrocellulose; GE Healthcare) at 90 V for
90 min on ice in transfer buffer (48 mM Tris/HCl, 39 mM glycine, 20% v/
v methanol). Transferred membranes were blocked with 5% w/v nonfat dry
milk dissolved in TBS-T (20 mM Tris/HCl (pH 7.5), 150 mM NaCl, and
0.1% v/v Tween 20) at room temperature for 1 h. Membranes were then incu-
bated with primary antibodies overnight at 4C. After washing membranes in
TBS-T 3  15 min, membranes were incubated with secondary antibodies at
room temperature for 1 h. After washing membranes in TBS-T 3  15 min,
membranes were scanned using LI-COR Odyssey CLx. Protein band inten-
sities were analyzed using LI-COR Image Studio Lite software.RESULTS AND DISCUSSION
Structural comparisons of Rab8a complexes with
RILPL2
The structure of GTP-bound pRab8(Q67L) in complex with
RL2117 forms crystals with one molecule of pRab8a and one
molecule of RILPL2 as the repeating unit. The biological het-
erotetramer is generated by a twofold crystallographic axis
down the length of the central parallel a-helical dimer of
RL2117. In the biological assembly, the effector bridges two
molecules of Rab8 via hydrophobic and polar interactions.
TheX-cap is formed at the top of thea-helices, and it is critical
for positioning the effector to enable direct contacts between
R132RL2 and pT72R8. The structure resembles the reported
complex of pRab8a in complex with RL2129 (Fig. 1 B), in
which the asymmetric unit was the biologically relevant het-
erotetramer (6). In this previous structure with the minimal
RBD, the salt bridge between pT72R8 and R132RL2 was
well ordered, but the distal R130RL2 displayed considerable
flexibility. In contrast, the structure of pRab8a in complex
with RL2117 reveals a well-ordered R130RL2 that stacks
against R132RL2 (Fig. 1 C). This stable arrangement of the
dual arginines may enable formation of a symmetric twofold
crystallographic axis. In the ensuing discussions, stackingwill
refer to planarp-p interactions of the guanidino side chains of
arginines. Crystallographic details are shown in Table 1.74
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FIGURE 1 Structure of pRab8a:RL2117 complex
reveals Arg/Arg stacking. (A) Domain organization
of RILPL2 and Rab8a is shown. The N-terminal
RH1 domain of RILPL2 binds to myosin Va. The
hinge region between RH1 and RH2 domains is
predicted to be flexible from secondary structure
analyses. (B) Overall view of the pRab8a:RL2117
heterotetramer is shown. Dashed rectangle is the
X-cap that is seen up close in (C) and (D). Cyan
sphere is an Mg2þ ion that interacts with GTP
and switch 1 of pRab8a. (C) Left: structure of pRa-
b8a:RL2129 in the region of X-cap. H128RL2 is a
non-native residue that comes from the hexahisti-
dine affinity tag. Right: structure of pRab8a:RL2117
at the X-cap is shown. R130RL2 stacks against the
guanidino group of R132RL2. Comparisons of argi-
nine conformations at the interfaces are highlighted
with the shaded circle for complexes in (B) and (C).
To see this figure in color, go online.
Waschb€usch et al.Although the RBD of the complex begins at 117, residues
117–125 are disordered. The model contains residues 126–
161 of RILPL2 and resembles closely the minimal RBD
(129–161) of the previous structure (pRab8a:RILP129 com-
plex). There are no additional interactions with pRab8a,
and upon superposition, equivalent backbone residues have
a root mean-square deviation of 1.44 Å. The only significant
difference between the complexes is the conformation of
R130RL2, which is discussed in more detail below. As a
further comparison, the structure of a phosphomimetic
mutant Rab8a-T72E (Rab8TE) in complex with RILP129 has
also been determined. The complex Rab8TE:RILP129 crystal-
lizes in the same space group as pRab8a:RILP129 (Table 1),
and again, there are no significant differences at the interface.
The three complexes afford an excellent opportunity to
investigate the structural and thermodynamic details of phos-
pho-Rab binding by effectors. Electron density maps revealBPJ 11074
1850 Biophysical Journal 120, 1846–1855, May 4, 2021that one side of the E72R8:R132RL2 interaction in the
Rab8TE:RL2129 complex is well ordered and mimics the
pT72R8:R132RL2 salt bridge. However, the opposite side
shows some flexibility as evidenced by the poor density and
geometry (Fig. 2 A). In contrast, the key pT72R8:R132RL2
interaction in the pRab8a:RILP129 complex is well ordered,
suggesting a stronger salt bridge with phosphothreonine
(Fig. 2 B). There is also partial stacking of the R132/R130
side chains in the two complexes with the minimal
(RILP129) RBD. R130RL2 in the complex pRab8:RILP129 re-
veals better stacking relative to Rab8TE, but there remains
considerable flexibility as evidenced by electron density
maps (Fig. 2 B).
Strikingly, the newly determined structure of pRa-
b8a:RL2117 reveals an ordered R130 side chain that forms
strong stacking interactions with the guanidino group of
R130 (Fig. 2 C). As a measure of the close contacts, the
FIGURE 2 Electron density at the phosphate recognition motif of RILPL2. The contour level for all figures is at 1.5s. The asymmetric unit is the phys-
iological 2:2 complex for (A) and (B), whereas the pRab8:RL2117 is a 1:1 complex in the crystal. RL2, RILPL2; R8, Rab8a. (A) Complex Rab8TE:RL2129
reveals disorder and poor contacts for one of the E72R8:R132RL2 interactions. (B) For the complex pRab8a:RL2129, both pT72R8:R132RL2 contacts are well
ordered. However, the R130 side chain is flexible. (C) In the pRab8a:RL2117 complex, both R130RL2 and R132RL2 are well ordered and are involved in gua-
nidino stacking interactions. To see this figure in color, go online.
Dual arginine binding of phospho-Rabsdistance between R130(Nε) and R132(NH2) is 3.4 Å. In
contrast to the other complexes, pRab8a:RILP117 forms a sym-
metric twofold axis down the length of the coiled coil. There-
fore the two salt bridges between pT72 and R132 are identical
by symmetry in the biological heterotetramer. Rab8TE:RL2129
and pRab8a:RL2129 assemble as heterotetramers in the lattice.
As suggested previously, it is possible that conformational
flexibility in R130/R132 may prevent a symmetric twofold
axis from forming in the other two complexes. Previously,
we reported that R130RL2was essential for complex formation
in cells. In the context of full-length RILPL2, even a mutation
to lysine (R130K) significantly reduced the interaction with
pRab8a (6). However, the contribution of this distal arginine
to complex formation was unclear because the side chain
was relatively disordered. Given the short RBD (129–165) in
previous work, we could not exclude the possibility that both
R130 and R132 might directly interact with pT72R8 in longer
variants of RILPL2. Here, the structure of pRab8a with an
extended RBD–RL2117 suggests that R130RL2 contributes to
p-p stacking interactions with R132RL2 and stabilizes its salt
bridge with pT72R8. A lysine residue (R130K) cannot substi-
tute for this interaction, thus providing a rationale for the
inability of a positive charge to maintain binding to pRab8a.Thermodynamics of complex formation
In vitro pulldowns were performed to qualitatively assess the
affinities of the three complexes (Fig. 3A). These experiments
suggested that full-length RILPL2 (1–211) has less affinity to
pRab8a relative to the truncated variant RL2117. Although the
invitro reduction in affinity appears tobemodest, thefinding is
surprising because effectors are modular and RBD interac-BPJ 110tions with Rabs are generally independent of other domains
(5). Isothermal titration calorimetry (ITC) was then exploited
to providemore insight into the binding affinities (Fig. 3B; Ta-
ble 2). The data reveal that the affinity between pRab8a and
RL2117 is significantly stronger than other complexes, with a
more robust enthalpy contributing to complex formation
(Fig. 3 B). As discussed previously, comparisons of the
three complexes—Rab8TE:RL2129, pRab8:RL2129, and
pRab8:RL2117—reveal no significant differences apart from
the side chain of R130. Therefore, the increased enthalpic
contribution to the binding affinity can be attributed to a stron-
ger salt bridge between pT72R8 and R132RL2 (Fig. 3 C).
Although the distal R130RL2 is relatively far from the nearest
phosphate oxygen (5.6 Å), it may also contribute to the
enthalpy through long-range electrostatic interactions. The
bar graph of free-energy signatures (DH, TDS) also indicates
that the entropic term contributes favorably toward formation
of all of the complexes.However, the enthalpic gains are coun-
tered by a reduced entropic contribution, which can partially
be attributed to ordered guanidino side chains. The complexes
Rab8TE:RL2129 and pRab8:RL2129 have a similar Kd, but
favorable enthalpy for the pT72:R132 interaction is offset by
a reduction in the entropic gains (Fig. 3 D; Table 2). Intrigu-
ingly, relative to the truncated RL2117 variant, full-length
RILPL2 has a reduced affinity to pRab8a with less favorable
enthalpy. The N-terminal RH1 domain appears to antagonize
the interactions between pRab8 and theRH2domain by an un-
known mechanism that requires further investigation.
In addition to complexes, we also determined the structure
of uncomplexed Rab8TE. This was performed to support the
hypothesis that thermodynamic parameters can be attributed
to complex formation rather than intrinsic structural changes74
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FIGURE 3 Extended RBD of RILPL2 enhances
the enthalpic contribution to the binding affinity.
(A) In vitro pulldown of pRab8a with hexahisti-
dine-tagged RILPL2 variants. Each pulldown was
performed in duplicate with 10 mM concentrations
of bait and prey proteins. Domain organization of
RILPL2 is above the pulldown. Asterisk in the
phos-tag control gel is a Rab8a sample to show pu-
rity of pRab8a in pulldowns. (B) ITC titrations of
Rab8a into RILPL2 are shown. Typical concentra-
tions were 400–600 mM pRab8a/Rab8TE and 40–
60 mM RILPL2 variants. (C) Comparisons of the
structures of pRab8a:RILP129 and pRab8a:RILP117
are shown. The key difference at the interface is the
conformation of R132RL2. (D) Enthalpy and en-
tropy terms from ITC data (Table 2) are represented
as a bar graph. The trends show that increasing en-
thalpic contributions are balanced by an entropic
cost to complex formation. ITC values were calcu-
lated from the mean and standard deviations of 3
independent measurements. To see this figure in
color, go online.
Waschb€usch et al.from the negative charge at switch 2. The structure of Rab8TE
reveals no significant conformational differences in the over-
all fold relative to the complex Rab8TE:RL2129 (Fig. S1).TABLE 2 Thermodynamics of RILPL2 binding to pRab8a/
Rab8TE
Kd (mM) DH (kcal/mol) TDS (cal/kmol) N
Rab8TE(Q67L)
RL2129 3.4 5 0.5 2.7 5 0.3 4.6 5 0.5 1.03 5 0.05
pRab8a(Q67L)
RL2129 3.3 5 0.4 5.1 5 0.4 2.2 5 0.4 0.92 5 0.2
RL2117 0.54 5 0.1 7.4 5 0.2 1 50.3 1.1 5 0.15
RL2-FL 1.4 5 0.3 1.4 5 0.3 6.4 5 1.2 1.04 5 0.1
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1852 Biophysical Journal 120, 1846–1855, May 4, 2021Similarly, the recent structure of phosphorylated Rab8a at
S111 is identical to the unphosphorylated variant (17).
Although the structure of uncomplexed pRab8a-pT72 has
not yet been determined, it is likely that phosphorylated
Rabs do not undergo significant conformational changes
upon complex formation with RILPL2.Mutagenesis and cellular assays
Mutational and cellular analyses of RILPL2 residues preced-
ing R130RL2 were performed to assess the contribution of
this segment to pRab8a binding (Fig. 4). GFP-tagged full-
length RILPL2 variants were overexpressed in HEK293 cells
together with HA-tagged Rab8a and Flag-tagged LRRK2
FIGURE 4 Mutational and cellular assays suggest an extended RBD
contributes to pRab8a binding. (A) Coimmunoprecipitation studies of
overexpressed RILPL2 and pRab8a. HEK293 cells were transiently trans-
fected with constructs expressing Flag LRRK2[Y1699C], HA-Rab8a, and
WT or mutant RILPL2-GFP. At 48 h post-transfection, cells were treated
with 5500 nM MLi-2 for 90 min and then lysed. Upper panel: labeled
IP:GFP:RILPL2-GFP was immunoprecipitated using GFP binder Sephar-
ose and immunoprecipitates evaluated by immunoblotting with the indi-
cated antibodies. Immunoblots were developed using the LI-COR
Odyssey CLx Western blot imaging system with the indicated antibodies
at 0.5–1 mg/mL concentration. Lower panel, labeled input: 10 mg whole-
cell lysate was subjected to LI-COR immunoblot analysis. Each lane rep-
resents cell extract obtained from a different dish of cells. Similar results
were obtained in three separate experiments. (B) Quantification of pull-
down intensities from multiple repetitions. The yellow circles denote a
reduction in binding for mutants. Error estimates are the mean and stan-
dard deviation of 3 independent measurements. (C) Sequence alignment
of the predicted X-cap regions of the phospho-Rab-binding family of
effector proteins. Red circles above the sequence of RILPL2 indicate a se-
vere defect on pRab8a binding upon mutagenesis. Yellow circles indicate
a partial defect on the binding to pRab8a. Lines and arrow above the
alignment correspond to the secondary structure (loop, b-strand) of
RILPL2. To see this figure in color, go online.
Dual arginine binding of phospho-Rabs
BPJ 110Y1699C to ensure maximal phosphorylation of Rab8a.
LRRK2 specific inhibitor Mli-2 was used at 500 nM concen-
tration for 90 min as a control. RILPL2 was immunoprecip-
itated using anti-GFP resin, and the samples were subjected
to immunoblotting. These studies reveal that single mutants
D124ARL2 and D127ARL2 are partially defective in binding
to pRab8a (Fig. 4, A and B). The side-chain carboxylate of
D127RL2 is within 3 Å of the backbone NH groups of
N129RL2 and R130RL2. Although the geometry is not ideal,
these interactions may nevertheless contribute to stabiliza-
tion of the backbone conformation. It would also explain
why D127NRL2 does not have the same defect as
D127ARL2 (Fig. 4 A). The effects of mutations are mapped
as hotspots on a sequence alignment of the predicted X-cap
of effector proteins (Fig. 4, B and C). There are modest
sequence similarities in the upstream region preceding
R130 within the RILP family. Red circles denote hotspots
in which any mutation abolishes binding in cells (explored
in our previous publication (6)), whereas yellow circles
denote an intermediate phenotype. The molecular basis for
the contribution of D124RL2 to phospho-Rab recognition is
unknown because the segment 117–125 is flexible in electron
density maps.CONCLUSION
Phosphorylation of Rab GTPases has emerged as a regulato-
ry mechanism for membrane trafficking in a variety of con-
texts (3). The switch 2 a-helix of Rab GTPases is a hotspot
for phosphorylation, and its modification is likely to influ-
ence subsequent interactions with GAPs, GEFs, and effector
proteins. Here, we show that the conformation of arginine
residues from RILPL2 involved in pRab8a recognition is
sensitive to the region preceding the RBD. In particular,
distal R130RL2 is flexible, without a stabilizing influence
from upstream residues. However, the full-length effector
comprising both RH1/RH2 domains dramatically reduces
the enthalpy of complex formation, suggesting that the
distal R130 is disordered. The structural and thermody-
namic studies also suggest that the enthalpic gain from the
salt bridge between R132/pT72 is offset by a reduction in
favorable entropy arising from the ordering of the guanidino
side chains of R130/R132. A video is shown with the three
complexes as a trajectory (Rab8TE:RILP129/ Rab8TE:R-
ILP129/pRab8:RILP117) using the Morph application in
Chimera (Video S1; 18). Despite the lack of any additional
interactions, the upstream segment of RILPL2 appears to
stabilize the conformations of the two arginines for optimal
interactions with pRab8a. Cation-p and p-p interactions
that involve aromatic residues are widely known for their
stabilizing influence in a variety of contexts. However, argi-
nine clusters are increasingly being recognized for their
contribution to protein complex formation (19–21). Confor-
mational dynamics of RILPL2 have also previously been
observed in its interactions with Rab36 and myosin Va (22).74
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FIGURE 5 Comparisons of the recognition mo-
tifs in phosphodependent signaling complexes.
Phosphorylated proteins are in yellow, and recogni-
tion motifs are cyan. (A) Forkhead-associated
domain (FHA) in complex with a phosphothreo-
nine peptide (PDB: 1g6g (23)). (B) Complex of
p120RasGAP with a phosphotyrosine peptide
from p190RhoGAP (PDB: 6pxc (24)) is shown.
(C) Complex of pRab8a:RL2117 is shown. The
recognition motif for pT72R8 is more peripherally
associated relative to other known structures. To
see this figure in color, go online.
Waschb€usch et al.The structures of numerous signaling complexes involving
phosphorylated peptides have been determined. In general,
the peptides adopt an extended conformation, and the phos-
phorylated side chains are deeply embedded, with interac-
tions on both sides of the phosphate moiety (Fig. 5, A and
B). In contrast, the RILPL2 interaction with the phosphory-
lated switch 2 helix is more peripheral (Fig. 5 C). This
more subtle interaction motif in the pRab8a:RILPL2 complex
may be influenced by the upstream hinge region that connects
the RH1 domain to the RH2 domain. We have shown previ-
ously that myosin Va binding to the RH1 domain enhances
the affinity of the RH2 domain to pRab8a (6). An attractive
mechanistic model is that myosin binding facilitates a confor-
mation for the hinge region that enables recognition of
pRab8a by a dual arginine motif. Myosin binding to the
RH1 domain may enable ordering of the distal arginine
(R130), which would enhance the stability of the salt bridge
between R132 and pT72 of Rab8a. One prediction from this
model is that myosin:RILPL2 complexes are more likely to
be recruited to phospo-Rab8a membranes downstream of
LRRK2 activation.SUPPORTING MATERIAL
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